Investigational Drug Information for Vactosertib
✉ Email this page to a colleague
What is the drug development status for Vactosertib?
Vactosertib is an investigational drug.
There have been 20 clinical trials for Vactosertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2021.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Adenocarcinoma, and Neoplasms. The leading clinical trial sponsors are MedPacto, Inc., Merck Sharp & Dohme Corp., and AstraZeneca.
There are ninety-seven US patents protecting this investigational drug and seventy international patents.
Summary for Vactosertib
| US Patents | 97 |
| International Patents | 70 |
| US Patent Applications | 268 |
| WIPO Patent Applications | 150 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 1 (2021-06-01) |
| Vendors | 57 |
Recent Clinical Trials for Vactosertib
| Title | Sponsor | Phase |
|---|---|---|
| Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma | Sakti Chakrabarti | PHASE2 |
| Assessing Clinical Trial Outcome of Patients With Relapsed/Refractor Metastatic Osteosarcoma in Adolescents and Adults | MedPacto, Inc. | Phase 1/Phase 2 |
| Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor | Yonsei University | Phase 2 |
Clinical Trial Summary for Vactosertib
Top disease conditions for Vactosertib
Top clinical trial sponsors for Vactosertib
US Patents for Vactosertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Vactosertib | ⤷ Start Trial | Pharmaceutical composition for preventing or treating cancer and method using thereof | Medpacto Inc | ⤷ Start Trial |
| Vactosertib | ⤷ Start Trial | Antisense-oligonucleotides as inhibitors of TGF-R signaling | NeuroVision Pharma GmbH (Grunwald, DE) | ⤷ Start Trial |
| Vactosertib | ⤷ Start Trial | 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same | Frequency Therapeutics, Inc. (Woburn, MA) | ⤷ Start Trial |
| Vactosertib | ⤷ Start Trial | Methods and compositions for treating cancer using P2RX2 inhibitors | Flagship Pioneering Innovations V, Inc. (Cambridge, MA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Vactosertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Vactosertib | Australia | AU2015345006 | 2034-11-16 | ⤷ Start Trial |
| Vactosertib | Australia | AU2020257116 | 2034-11-16 | ⤷ Start Trial |
| Vactosertib | Australia | AU2020260380 | 2034-11-16 | ⤷ Start Trial |
| Vactosertib | Brazil | BR112017006201 | 2034-11-16 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
